SCHEMBL265393

SCHEMBL265393

O=C(Nc1ccc(Cl)c(C(=O)Nc2cnc(Nc3ccc(OCCN4CCCC4)cc3)nc2)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 10/20 0.64
SRC P12931 2/20 0.60
JAK2 O60674 2/20 0.60
LCK P06239 10/20 0.57
CSF1R P07333 5/20 0.57
MAPK14 Q16539 4/20 0.57
ABL1 P00519 1/20 0.57
FYN P06241 1/20 0.57
LYN P07948 1/20 0.57
KDR P35968 1/20 0.57
MAPK9 P45984 1/20 0.57
TEK Q02763 1/20 0.57
PDGFRB P09619 1/20 0.56
FGFR1 P11362 1/20 0.56
CYP2C9 P11712 1/20 0.56
BRAF P15056 1/20 0.56
EPHB4 P54760 1/20 0.56
PTK2 Q05397 1/20 0.56
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500715 0.95 BTK (0.68) BTKSRCJAK2LCKCSF1R
SCHEMBL2495224 0.93 LCK (0.57) BTKSRCJAK2LCKCSF1R
SCHEMBL2492783 0.92 BTK (0.53) BTKSRCJAK2LCKCSF1R
SCHEMBL2493709 0.91 LCK (0.70) BTKSRCJAK2LCKCSF1R
SCHEMBL12190170 0.90 CSF1R (0.54) BTKSRCJAK2LCKCSF1R
SCHEMBL2495666 0.90 SRC (0.62) BTKSRCJAK2LCKCSF1R
SCHEMBL2493814 0.89 BTK (0.59) BTKSRCJAK2LCKCSF1R
SCHEMBL2495207 0.88 BTK (0.64) BTKSRCJAK2LCKCSF1R
SCHEMBL2499022 0.88 BTK (0.64) BTKSRCJAK2LCKCSF1R
SCHEMBL14304919 0.86 SRC (0.59) BTKSRCJAK2LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360129-A1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2025-11-27 US claimed
EP-3250192-B1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2025-10-08 EP claimed
US-12350261-B2 Methods and devices for the treatment of ocular diseases in human subjects CLEARSIDE BIOMEDICAL, INC. (US) 2025-07-08 US claimed
US-20230036788-A1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2023-02-02 US claimed
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles CLEARSIDE BIOMEDICAL, INC. (US) 2026-05-28 US disclosed
US-20260048008-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF OCULAR THERAPEUTIX INC (US) 2026-02-19 US disclosed
EP-4695324-A1 BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY Ocular Therapeutix, Inc. (US) 2026-02-18 EP disclosed
EP-4683964-A2 POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2026-01-28 EP disclosed
US-20250360129-A1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2025-11-27 US disclosed
EP-4653015-A2 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS Yale University (US) 2025-11-26 EP disclosed
US-20250345206-A1 APPARATUS AND METHODS FOR OCULAR INJECTION CLEARSIDE BIOMEDICAL, INC. (US) 2025-11-13 US disclosed
EP-3250192-B1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2025-10-08 EP disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048008-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF KIT, IL33, LY96 BTK 92/4885SRC 184/4885JAK2 1902/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 BTK 9/4885SRC 80/4885JAK2 1/4885
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles PROKR2, SLC10A2, GLP1R BTK 398/4885SRC 613/4885JAK2 12/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 BTK 9/4885SRC 80/4885JAK2 1/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 BTK 9/4885SRC 80/4885JAK2 1/4885
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 BTK 44/4885SRC 5/4885JAK2 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.